Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Posted by Karen Goldfarb
November 11, 2022 at 4:11 PM
Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
Posted by Karen Goldfarb
August 5, 2022 at 4:02 PM
Crystal Research Associates has issued a 19-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
Posted by Karen Goldfarb
April 29, 2022 at 1:23 PM
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19
Posted by Karen Goldfarb
March 14, 2022 at 6:22 PM
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19
Posted by Karen Goldfarb
November 17, 2021 at 9:28 AM
Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus
Posted by Karen Goldfarb
October 4, 2021 at 11:13 AM
Crystal Research Associates has issued a 6-page update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ) following its announcement of an Assignment and License Agreement with PNP Therapeutics, Inc. (“PNP”), granting GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product to treat solid tumors.
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus
Posted by Karen Goldfarb
August 15, 2021 at 6:35 PM
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus
Crystal Research Associates has issued an 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus
Posted by Karen Goldfarb
March 29, 2021 at 2:53 PM
Crystal Research Associates has issued an 14-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus
Posted by Karen Goldfarb
February 16, 2021 at 10:13 AM
Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus
Posted by Karen Goldfarb
November 11, 2020 at 10:24 AM
Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus
Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVXD-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv
Posted by Karen Goldfarb
March 31, 2019 at 8:52 PM
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv
Posted by Karen Goldfarb
January 23, 2019 at 10:40 AM
GeoVax announced that it has been nominated for the 2019 ViE (Vaccine Industry Excellence) Awards in three categories. Please use the following link to vote for these special industry awards in the follow categories:
https://www.surveymonkey.co.uk/r/J39ZFW3
For more information on GeoVax, please read to our most recent Quarterly Update dated November 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.
*******************************************
Visit our Corporate Profile and Key Points pages
for the latest research on GeoVax Labs, Inc.
*******************************************
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv
Posted by Karen Goldfarb
December 4, 2018 at 10:04 AM
GeoVax announced that it has been nominated in the Public Company category at the Buzz of BIO Contest, recognizing the Company as one of the most innovative companies at the upcoming 2019 CEO & Investor Conference sponsored by the Biotechnology Innovation Organization (BIO).
Please vote for GeoVax at https://www.bio.org/events/
GeoVax's development programs are importantly focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .
For more information on GeoVax, please refer to our most recent Quarterly Update dated November 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.
*******************************************
Visit our Corporate Profile and Key Points pages
for the latest research on GeoVax Labs, Inc.
*******************************************
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.
CONTACT INFORMATION
880 Third Avenue, 6th Floor
New York, NY 10022
Phone: (212) 851-6685